The clinical and neuromechanisms research for Shizhen Anshen granules treatment on cognitive impairments of first episode schizophrenia

Not Applicable

Recruiting

• Conditions: Schizophrenia

• Registration Number: ITMCTR2000003308
• Lead Sponsor: Beijing Anding Hospital, Capital Medical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Patients who meet the criteria of first-episode schizophrenia stipulated in the study;
2. Patients aged 18-40 (including 18 and 40 years old);
3. Patients who voluntarily sign the informed consent and are able to follow the research program;
4. Patients who can understand the follow-up questionnaire;
5. Patients who meet the criteria of syndrome type of kidney yin deficiency and fire hyperactivity of TCM in psychiatry (hallucination, delusion, weird thinking, scattered thinking, dull and little speech, self talk and self laugh, alone in a corner, sore waist and knees, dry mouth, constipation, red tongue, little moss, teeth marks, fine pulse strings).

Exclusion Criteria

1. Objects with serious suicidal tendencies;
2. Patients with depressive episode;
3. Patients with serious or unstable heart, liver, kidney, endocrine, blood and other medical diseases;
4. The patients who took antipsychotic drugs in the first 4 weeks were selected;
5. Patients without supervision;
6. Patients with PANSS score reduction rate >= 25% at baseline compared with those at screening.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
P300, PPI;cognitive function;

Secondary Outcome Measures

Name	Time	Method
functional connectivity;symptoms assessment;